^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PH-762 ACT
i
Other names: PH-762 ACT, RXI-762 ACT
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Phio Pharma
Drug class:
PD1 inhibitor
Related drugs:
over1year
Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762 (SITC 2022)
Conclusions We have generated a potent tumor-specific ACT TIL product (AGX148) at clinical scale through the isolation and selective expansion of tumor-reactive T cells. Knocking down PD-1 with PH-762 INTASYL™ has the potential to further enhance the function of the AGX148 product and this ACT product will soon be tested in cancer patients.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • ITGAE (Integrin Subunit Alpha E) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
AGX-148 • PH-762 ACT
Share via
